QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:TNDM

Tandem Diabetes Care Stock Forecast, Price & News

$91.30
-0.47 (-0.51 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$90.73
Now: $91.30
$94.32
50-Day Range
$91.35
MA: $96.94
$104.34
52-Week Range
$43.69
Now: $91.30
$123.74
Volume1.19 million shs
Average Volume668,402 shs
Market Capitalization$5.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.31
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin delivery system with Basal-IQ Technology; t:slim X2 with control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Further, the company offers Sugarmate, a mobile app for people with diabetes who use insulin. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Tandem Diabetes Care logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900
Employees1,043
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$362.30 million
Book Value$3.30 per share

Profitability

Net Income$-24,750,000.00

Miscellaneous

Market Cap$5.56 billion
Next Earnings Date2/24/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

286th out of 1,958 stocks

Surgical & Medical Instruments Industry

27th out of 168 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$91.30
-0.47 (-0.51 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

Is Tandem Diabetes Care a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care
or view top-rated stocks.

What stocks does MarketBeat like better than Tandem Diabetes Care?

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Tandem Diabetes Care
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its quarterly earnings results on Thursday, November, 5th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.07. The medical device company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $115.16 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 10.98% and a negative net margin of 11.10%. The company's quarterly revenue was up 30.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) EPS.
View Tandem Diabetes Care's earnings history
.

How has Tandem Diabetes Care's stock been impacted by Coronavirus (COVID-19)?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TNDM shares have increased by 37.6% and is now trading at $91.30.
View which stocks have been most impacted by COVID-19
.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600-615 million, compared to the consensus revenue estimate of $563.05 million.

What price target have analysts set for TNDM?

13 equities research analysts have issued 12 month price targets for Tandem Diabetes Care's shares. Their forecasts range from $75.00 to $140.00. On average, they expect Tandem Diabetes Care's share price to reach $117.62 in the next year. This suggests a possible upside of 28.8% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care
or view top-rated stocks among Wall Street analysts.

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:
  • Mr. John F. Sheridan, Pres, CEO & Director (Age 66, Pay $1.24M)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 48, Pay $769.82k)
  • Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 42, Pay $768.61k)
  • Mr. David B. Berger, Exec. VP, Chief Bus. Operations & Compliance Officer and Corp. Sec. (Age 51, Pay $769.25k)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 53, Pay $778.26k)
  • Mr. Jim Leal, Sr. VP of Operations
  • Mr. Manuel Jaime, Sr. VP of Technology & Digital Health
  • Mr. Ross Sylvia, VP of Marketing
  • Ms. Elizabeth A. Gasser, Exec. VP of Strategy & Corp. Devel. (Age 45)
  • Mr. Tom Fox, Sr. VP of HR & Organizational Devel.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Who are some of Tandem Diabetes Care's key competitors?

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.71%), Jackson Square Partners LLC (5.23%), Credit Suisse AG (2.31%), Price T Rowe Associates Inc. MD (2.25%), Federated Hermes Inc. (2.09%) and Brown Capital Management LLC (2.01%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care
.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Columbus Circle Investors, Renaissance Technologies LLC, JPMorgan Chase & Co., Russell Investments Group Ltd., First Trust Advisors LP, Amundi Pioneer Asset Management Inc., and Federated Hermes Inc.. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care
or view top insider-selling stocks.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was purchased by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Delphi Management Partners VIII L.L.C., Credit Suisse AG, Sei Investments Co., Morgan Stanley, Eaton Vance Management, BlackRock Inc., and Cibc World Markets Corp.
View insider buying and selling activity for Tandem Diabetes Care
or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $91.30.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care has a market capitalization of $5.56 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

Tandem Diabetes Care employs 1,043 workers across the globe.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Where are Tandem Diabetes Care's headquarters?

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.